Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (51-60 of 773) with videos related to

Pageof 78
Sort By:
Expert Review of Anticancer Therapy|October 14, 2005
Thalidomide and dexamethasone: therapy for multiple myelomaShaji Kumar, S Vincent Rajkumar
The New England Journal of Medicine|December 30, 2025
Monoclonal Gammopathy of Undetermined Significance. ReplyS Vincent Rajkumar, Shaji Kumar
Leukemia|December 5, 2025
Measurable residual disease assessment in multiple myelomaSaurabh Zanwar, S Vincent Rajkumar
Oncology (Williston Park, N.Y.)|May 30, 2009
Emerging therapies for multiple myelomaDavid Dingli, S Vincent Rajkumar
Seminars in Hematology|April 25, 2009
Front-line treatment in younger patients with multiple myelomaS Vincent Rajkumar, Pieter Sonneveld
Blood Reviews|April 3, 2010
How best to use new therapies in multiple myelomaDavid Dingli, S Vincent Rajkumar
European Journal of Haematology|March 30, 2010
Multiple myeloma: chemotherapy or transplantation in the era of new drugsAntonio Palumbo, S Vincent Rajkumar
Mayo Clinic Proceedings|November 5, 2013
Monoclonal gammopathy-associated proliferative glomerulonephritisSanjeev Sethi, S Vincent Rajkumar
Blood Cancer Journal|September 29, 2020
Multiple myeloma current treatment algorithmsS Vincent Rajkumar, Shaji Kumar
JACC. Cardiooncology|October 10, 2022
Cardiovascular Associations With Monoclonal Gammopathy of Undetermined Significance: Real or Coincidental?Prashant Kapoor, S Vincent Rajkumar
Pageof 78

Showing results (51-60 of 773) with videos related to

Sort By:
Pageof 78
Expert Review of Anticancer Therapy|October 14, 2005
Thalidomide and dexamethasone: therapy for multiple myelomaShaji Kumar, S Vincent Rajkumar
The New England Journal of Medicine|December 30, 2025
Monoclonal Gammopathy of Undetermined Significance. ReplyS Vincent Rajkumar, Shaji Kumar
Leukemia|December 5, 2025
Measurable residual disease assessment in multiple myelomaSaurabh Zanwar, S Vincent Rajkumar
Oncology (Williston Park, N.Y.)|May 30, 2009
Emerging therapies for multiple myelomaDavid Dingli, S Vincent Rajkumar
Seminars in Hematology|April 25, 2009
Front-line treatment in younger patients with multiple myelomaS Vincent Rajkumar, Pieter Sonneveld
Blood Reviews|April 3, 2010
How best to use new therapies in multiple myelomaDavid Dingli, S Vincent Rajkumar
European Journal of Haematology|March 30, 2010
Multiple myeloma: chemotherapy or transplantation in the era of new drugsAntonio Palumbo, S Vincent Rajkumar
Mayo Clinic Proceedings|November 5, 2013
Monoclonal gammopathy-associated proliferative glomerulonephritisSanjeev Sethi, S Vincent Rajkumar
Blood Cancer Journal|September 29, 2020
Multiple myeloma current treatment algorithmsS Vincent Rajkumar, Shaji Kumar
JACC. Cardiooncology|October 10, 2022
Cardiovascular Associations With Monoclonal Gammopathy of Undetermined Significance: Real or Coincidental?Prashant Kapoor, S Vincent Rajkumar
Pageof 78